{
    "clinical_study": {
        "@rank": "99293", 
        "acronym": "StivargaPMS", 
        "arm_group": {
            "arm_group_label": "Group 1", 
            "description": "Patients treated by Physician with Stivarga under approved local prescriptions"
        }, 
        "brief_summary": {
            "textblock": "To investigate and collect post-marketing data on the safety of Stivarga in real world\n      practice in its registered indication(s) as required by Health Authority"
        }, 
        "brief_title": "Stivarga Regulatory Post-Marketing Surveillance Study in Korea", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Inclusion Criteria:\n\n          -  Patients diagnosed with metastatic colorectal cancer or metastatic or unresectable\n             locally advanced GIST(gastrointestinal stromal tumors) by physician.\n\n          -  Patients who are prescribed with Stivarga for the first time\n\n          -  Exclusion Criteria:\n\n          -  All contra-indications according to the local marketing authorization have to be\n             considered"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients diagnosed with metastatic colorectal cancer or metastatic or unresectable locally\n        advanced GIST(Gastrointestinal stromal tumors) by physician"
            }
        }, 
        "enrollment": {
            "#text": "3750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106858", 
            "org_study_id": "16778", 
            "secondary_id": "SV1314KR"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "intervention_name": "Regorafenib (Stivarga,BAY73-4506)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Stivarga / Regorafenib / Metastatic Colorectal Cancer / Metastatic or unresectable locally advanced GIST (Gastrointestinal stromal tumors)", 
        "lastchanged_date": "June 3, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Stivarga\u00ae Regulatory Post-Marketing Surveillance Study in Korea", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food & Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Every 2 months (monthly safety assessment within first two cycles)", 
                "measure": "Percentage of patients with serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days after terminating treatment"
            }, 
            {
                "description": "Every 2 months (monthly safety assessment within first two cycles)", 
                "measure": "Percentage of patients with adverse drug reactions (ADRs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days after terminating treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106858"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall response", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 years"
            }, 
            {
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 years"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 years"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}